Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Core Points - Belite Bio, Inc has announced a private placement in public equity financing (PIPE) expected to generate approximately $125 million in gross proceeds, with potential additional proceeds of about $150 million if warrants are fully exercised [1][3][8] Company Overview - Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases, specifically targeting Stargardt disease and geographic atrophy in advanced dry age-related macular degeneration [9] Financing Details - The PIPE will involve the issuance of 1,953,124 ordinary shares and warrants at a purchase price of $64.00 per share, with warrants exercisable at a 20% premium [3][8] - The closing of the PIPE is anticipated to occur on or about September 9, 2025, pending customary closing conditions [3] Use of Proceeds - The net proceeds from the PIPE will be utilized for commercialization preparation, working capital, and general corporate purposes [4]